Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: Data from the ICONA foundation cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages 339-345

  Mussini, Cristina ^a   Galli, Laura ^b   Lepri, Alessandro C ^c   De Luca, Andrea ^d   Antinori, Andrea ^e   Libertone, Raffaella ^e   Angarano, Gioacchino ^f   Bonfanti, Paolo ^g   Castagna, Antonella ^b   D'Arminio Monforte, Antonella ^h  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g A MANZONI HOSPITAL   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretroviral naive patients; Bacterial pneumonia; Incidence; Risk factors

Indexed keywords

ANTIINFECTIVE AGENT; HEMOGLOBIN; HEPATITIS C ANTIBODY; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CHLAMYDIA; CLINICAL EXAMINATION; FEMALE; FOLLOW UP; HAEMOPHILUS; HEMATOLOGICAL PARAMETERS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; KLEBSIELLA PNEUMONIAE; LEGIONELLA; LEUKOCYTE COUNT; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIA; NEUTROPHIL COUNT; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; SMOKING; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PNEUMONIA, BACTERIAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VIRAL LOAD;

EID: 84880209688     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318295ab85     Document Type: Article

References (39)

1. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med. 2007;8:547-554.
2. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005; the "mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
3. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ. 2022;51:1-16.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349: 1498-1504.
5. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121:121S-126S.
6. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97:115-122.
7. Kohli R, Lo Y, Howard AA, et al. Mortality in a urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;41:864-872.
8. Sullivan JH, Moore RD, Keruly JC, et al. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med. 2000;162:64-67.
9. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy and disease progression among HIV-infected women in HIV Epidemiologic Research (HER) Study. Clin Infect Dis. 2006;43:90-98.
10. Osmond DH, Chin DP, Glassroth J, et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Clin Infect Dis. 1999;29:536-543.
11. Crothers K, Butt AA, Gibert CL, et al; for the Veterans Aging Cohort 5 Project Team. Increased COPD among HIV-positive compared to HIV-negative veterans. CHEST. 2006;130:1326-1333.
12. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145-1155.
13. Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178:630-636.
14. Le Moing V, Rabaud C, Journot V, et al. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med. 2006;7:261-267.
15. Benard A, Mercie P, Alioum A, et al; The Groupe d'Epidemiologie Clinique du SIDA en Aquitane (GECSA). Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitane Cohort, 2000-2007. PLos One. 2008;5:e8896.
16. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumo-coccal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis. 2008;46:1093-1100.
17. Dworkin MS, Ward JW, Hanson DL, et al. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794-800.
18. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneu-mococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362:812-822.
19. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do pattern of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593-1601.
20. Gutierrez F, Masia M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006; 53:166-174.
21. Jensen-Fangel S, Mohey R, Johnsen SP, et al. Gender differences in hospitalization rates for respiratory tract infections in Danish youth. Scand J Infect Dis. 2004; 36:31-36.
22. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8:737-744.
23. Mocroft A, Reiss P, Kirk O; for Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count, 200 cells/microL? Clin Infect Dis. 2010;51:611-619.
24. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13:959-967.
25. Bansi L, Gazzard B, Post F, et al; for the UK Collaborative HIC Cohort (CHIC) Study. Biomarkers to monitor safety in people on ART and risk of mortality. J Acquir Immune Defic Syndr. 2012;60:51-58.
26. Justice AC, McGinnis KA, Shanderson M, et al; for the VACS Project Team. Towards a combined prognostic index for survival in HIV infection: the role of "non-HIV biomarkers. HIV Med. 2010;11:143-151.
27. Justice AC, Freiberg MS, Tracy R, et al; for the VACS Project Team. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54:984-994.
28. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
29. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91:2214-2221.
30. Shebl FM, Engels EA, Goedert JJ, et al. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr. 2010;55:375-379.
31. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest. 2001;120:1888-1893.
32. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005;165:1533-1540.
33. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164:2206-2216.
34. Niaura R, Shadel WG, Morrow K, et al. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31:808-812.
35. Drach L, Holbert T, Maher J, et al. Integrating smoking cessation into HIV care. AIDS Patient Care STDS. 2010;24:139-140.
36. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
37. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560-2567.
38. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
39. When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.